Latest Product Launch News

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

Straker Ltd has reported a record adjusted EBITDA of NZ$4.8 million for FY25, driven by strong growth in AI subscription services and operational efficiencies, even as overall revenue declined 10.3%. The company’s strategic pivot towards AI-powered offerings signals a promising shift in its business model.

Yowie Group has posted its first profitable seasonal quarter, driven by strategic cost control and product improvements, but faces ongoing capital challenges due to a significant loan default by Keybridge Capital.

The Calmer Co. International Limited has significantly expanded the distribution of its flagship kava products in Coles supermarkets, reflecting growing consumer appetite for natural relaxation alternatives to alcohol.

Australian Vintage outlines a strategic turnaround with innovative product launches and a key acquisition, aiming to reverse declining sales and improve cash flow in FY2026.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

Catapult Group International Ltd reported a milestone FY25 with ACV exceeding US$100 million, driven by strong SaaS growth and record profitability. The company’s innovative product launches and improved cost efficiencies underpin a confident outlook for FY26.

Merino & Co has amended its quarterly report to correct expenditure figures and clarify related party payments, while reporting significant operational progress including new product launches and cryptocurrency integration.

Elixinol Wellness Limited reported a robust FY24 performance, achieving an 81% increase in revenue and significantly narrowing its losses. The company is now focused on scaling its direct-to-consumer channels and operational efficiencies to reach profitability in 2025.

ECS Botanics is on track for a record-breaking FY25 harvest with a 50% production increase and new premium product launches, signaling strong growth and a positive cash flow outlook.

Xero Limited has reported a robust FY25 with 23% revenue growth and a Rule of 40 score exceeding 44%, underscoring its balanced approach to growth and profitability.